ARTICLE | Management Tracks
Plus: Quirk takes on CEO role at Terns and an update from Structure
By Richard Guy, Biopharma Analyst, and Gunjan Ohri, Data Content Analyst
August 5, 2023 1:34 AM UTC
Deciphera Pharmaceuticals Inc. (NASDAQ:DCPH) said Dashyant Dhanak will succeed EVP and CSO Daniel Flynn, effective Sept. 5. Dhanak was CSO and EVP at Incyte Corp. (NASDAQ:INCY), having worked at Janssen Research & Development and GSK plc (LSE:GSK; NYSE:GSK). Flynn, who founded Deciphera, will transition to the role of senior adviser. The company also appointed Ron Squarer as chairperson, succeeding James Bristol, who will remain a board member. Squarer first joined the Deciphera’s board in 2019.
Terns Pharmaceuticals Inc. (NASDAQ:TERN) President and Head of R&D Erin Quirk is now CEO, following the resignation of Senthil Sundaram for health reasons. Sundaram also resigned from the company’s board, but will stay on with the company as a senior adviser. …
- SEO Powered Content & PR Distribution. Get Amplified Today.
- PlatoData.Network Vertical Generative Ai. Empower Yourself. Access Here.
- PlatoAiStream. Web3 Intelligence. Knowledge Amplified. Access Here.
- PlatoESG. Automotive / EVs, Carbon, CleanTech, Energy, Environment, Solar, Waste Management. Access Here.
- BlockOffsets. Modernizing Environmental Offset Ownership. Access Here.
- Source: https://www.biocentury.com/article/648830/dhanak-heads-to-deciphera
